Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005605 · ClinicalTrials.gov registry record
Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer
A clinical trial, sponsored by Northwestern University.
- Completed
- Registry status
- 79
- Enrollment target
NCT00005605 is a clinical trial that has completed, run by Northwestern University. The registered enrollment target is 79 participants.
The verdict
NCT00005605 has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
RATIONALE: Tamoxifen may be able to increase bone density and decrease cholesterol in women who are undergoing chemotherapy for breast cancer. PURPOSE: Clinical trial to study the effectiveness of tamoxifen in preventing bone loss and heart disease caused by chemotherapy treatment in premenopausal women who have stage I or stage II breast cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2000-02 |
| Est. Completion | 2005-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005605
The ClinicalTrials.gov registry entry for NCT00005605 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00005605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005605 about?
NCT00005605 is a clinical study titled "Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer". RATIONALE: Tamoxifen may be able to increase bone density and decrease cholesterol in women who are undergoing chemotherapy for breast cancer. PURPOSE: Clinical trial to study the effectiveness of tamoxifen in preventing bone loss and heart disease caused by chemotherapy treatment in premenopausal ...
What is the current status of trial NCT00005605?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2000-02. Estimated completion is 2005-10.
Who is sponsoring clinical trial NCT00005605?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.